Fusion Pharmaceuticals (NASDAQ:FUSN) Earns “Hold” Rating from TD Cowen

TD Cowen reaffirmed their hold rating on shares of Fusion Pharmaceuticals (NASDAQ:FUSN) in a research report sent to investors on Tuesday morning, Benzinga reports.

FUSN has been the topic of several other reports. Raymond James reiterated a market perform rating on shares of Fusion Pharmaceuticals in a research note on Tuesday, March 19th. Leerink Partnrs lowered shares of Fusion Pharmaceuticals from an outperform rating to a market perform rating in a research note on Tuesday, March 19th. Wedbush lowered shares of Fusion Pharmaceuticals from an outperform rating to a neutral rating and set a $24.00 target price on the stock. in a research report on Tuesday, March 19th. Brookline Capital Management lowered shares of Fusion Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, March 19th. Finally, Jefferies Financial Group restated a hold rating and set a $21.00 target price (up from $10.00) on shares of Fusion Pharmaceuticals in a research report on Tuesday, March 19th. Thirteen analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of Hold and a consensus target price of $20.25.

Fusion Pharmaceuticals Stock Performance

Shares of Fusion Pharmaceuticals stock opened at $21.25 on Tuesday. The firm has a market capitalization of $1.80 billion, a P/E ratio of -14.46 and a beta of -0.72. Fusion Pharmaceuticals has a 52 week low of $2.31 and a 52 week high of $21.55. The company has a quick ratio of 15.01, a current ratio of 15.01 and a debt-to-equity ratio of 0.16. The firm’s 50 day moving average is $15.87 and its two-hundred day moving average is $9.71.

Fusion Pharmaceuticals (NASDAQ:FUSN) last announced its quarterly earnings results on Wednesday, March 20th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.05). Fusion Pharmaceuticals had a negative net margin of 4,136.55% and a negative return on equity of 46.59%. Research analysts forecast that Fusion Pharmaceuticals will post -1.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Fusion Pharmaceuticals

Several hedge funds have recently modified their holdings of FUSN. Perceptive Advisors LLC acquired a new stake in shares of Fusion Pharmaceuticals during the first quarter worth $10,405,000. FMR LLC lifted its holdings in shares of Fusion Pharmaceuticals by 73.9% during the first quarter. FMR LLC now owns 4,681,457 shares of the company’s stock worth $17,649,000 after purchasing an additional 1,989,403 shares during the period. Federated Hermes Inc. lifted its holdings in Fusion Pharmaceuticals by 94.1% in the first quarter. Federated Hermes Inc. now owns 3,055,037 shares of the company’s stock valued at $23,738,000 after acquiring an additional 1,481,037 shares during the period. Sphera Funds Management LTD. acquired a new stake in Fusion Pharmaceuticals in the first quarter valued at $4,839,000. Finally, Wellington Management Group LLP acquired a new stake in Fusion Pharmaceuticals in the fourth quarter valued at $7,154,000. 72.85% of the stock is owned by institutional investors and hedge funds.

Fusion Pharmaceuticals Company Profile

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.